FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John McHutchison

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Hepacivirus

Procedures

Physiology

Genotype

Concepts & Ideas

Anatomy

Livers

Co-author Network

Publications

TOP 3
Eric J Lawitz; Thomas Marbury; Anita Mathias; John G McHutchison; Hongmei Mo; Lisa Moorehead; Maribel Rodriguez-Torres; Jenny Yang; William Delaney; Michael P Demicco; John M Hill; Stuart C Gordon
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Ziad F Gellad; Ira M Jacobson; David Kershenobich; Michael P Manns; John G McHutchison; Andrew J Muir; Kimberly A Brown; Robert Flisiak; Kevin A Schulman; Ala I Sharara; William Sievert; Shelby D Reed
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
Paul J Clark; Jacques Fellay; Dongliang Ge; David B Goldstein; Zachary Goodman; Stephen A Harrison; John G McHutchison; Susanna Naggie; Stephanie Noviello; Keyur Patel; Lisa Pedicone; Kevin Shianna; Mark S Sulkowski; Alexander J Thompson; Hans L Tillmann; Thomas J Urban; David M Vock; Mingfu Zhu; Qianqian Zhu; Nezam Afdhal; Janice K Albrecht; Andrew J Muir
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John McHutchison (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eric J Lawitz; Thomas Marbury; Anita Mathias; John G McHutchison; Hongmei Mo; Lisa Moorehead; Maribel Rodriguez-Torres; Jenny Yang; William Delaney; Michael P Demicco; John M Hill; Stuart C Gordon
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Antiviral therapy 2013;18(3):311-9.
2012: Ziad F Gellad; Ira M Jacobson; David Kershenobich; Michael P Manns; John G McHutchison; Andrew J Muir; Kimberly A Brown; Robert Flisiak; Kevin A Schulman; Ala I Sharara; William Sievert; Shelby D Reed
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(6):876-86.
2012: Paul J Clark; Jacques Fellay; Dongliang Ge; David B Goldstein; Zachary Goodman; Stephen A Harrison; John G McHutchison; Susanna Naggie; Stephanie Noviello; Keyur Patel; Lisa Pedicone; Kevin Shianna; Mark S Sulkowski; Alexander J Thompson; Hans L Tillmann; Thomas J Urban; David M Vock; Mingfu Zhu; Qianqian Zhu; Nezam Afdhal; Janice K Albrecht; Andrew J Muir
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.
Digestive diseases and sciences 2012;57(8):2213-21.
2012: Susanna Naggie; Anu Osinusi; Keyur Patel; Michael A Polis; Joerg F Schlaak; Bhavana Shivakumar; Alexander J Thompson; Martin Trippler; Paul J Clark; Eva Herrmann; Antonios Katsounas; Richard Lempicki; Henry Masur; John G McHutchison; Andrew J Muir; Shyam Kottilil
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Hepatology (Baltimore, Md.) 2012;56(2):444-54.
2012: Eric J Lawitz; John O Link; Thomas Marbury; Anita Mathias; John G McHutchison; Hongmei Mo; Lisa Moorehead; Kelly A Wong; Guofeng Cheng; Daniel Gruener; John M Hill; Diana M Brainard
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
Journal of hepatology 2012;57(1):24-31.
2012: P J Clark; R Esteban; Jacques Fellay; D Ge; David B Goldstein; S A Harrison; Paul Y Kwo; John G McHutchison; Andrew J Muir; S Naggie; S Noviello; Keyur Patel; Lisa Pedicone; K Shianna; Mark S Sulkowski; A J Thompson; Hans L Tillmann; T J Urban; D M Vock; M Zhu; Q Zhu; Nezam H Afdhal; Janice K Albrecht
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
Journal of viral hepatitis 2012;19(5):332-40.
2012: Alexander J Thompson; Hans L Tillmann; Thomas J Urban; Mingfu Zhu; Qianqian Zhu; Susanna Naggie; Stephanie Noviello; Keyur Patel; Lisa Pedicone; F Fred Poordad; Kevin V Shianna; Mitchell L Shiffman; Abanish Singh; Mark S Sulkowski; Nezam H Afdhal; Janice K Albrecht; Clifford A Brass; Paul J Clark; Rafael Esteban; Jacques Fellay; Greg W Galler; Dongliang Ge; David B Goldstein; Ira M Jacobson; John W King; Paul Y Kwo; Eric J Lawitz; Jonathan McCone; John G McHutchison; Andrew J Muir
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Journal of hepatology 2012;56(2):313-9.
2011: Hans L Tillmann; Paul J Clark; Stephen D Gardner; CD Guy; Xiang Qian Lao; Josephine H Li; John G McHutchison; Andrew J Muir; Keyur Patel; Alexander Thompson; Jeanette J McCarthy
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.
Journal of hepatology 2011;55(6):1195-200.
2011: Keyur Patel; Erik Pulkstenis; Eugene R Schiff; Carol Stanciu; G. SUBRAMANIAN; Michael Torbenson; Isabelle Colle; Mireen Friedrich-Rust; Guido Gerken; Mircea Grigorescu; Dieter Häussinger; Chuan-Mo Lee; Yoav Lurie; Michael P Manns; John G McHutchison; Stefan Zeuzem
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
World journal of gastroenterology : WJG 2011;17(41):4581-9.
2011: Andrew J Muir; Jean-Michel Pawlotsky; F Fred Poordad; Henk W Reesink; Mitchell L Shiffman; Stefan Zeuzem; Thomas Berg; Geoffrey Dusheiko; Peter Ferenci; Shelley George; E Jenny Heathcote; Robert S Kauffman; Emily C Martin; John G McHutchison; Nathalie Adda
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
Hepatology (Baltimore, Md.) 2011;54(5):1538-46.
2011: X Q Lao; John G McHutchison; A Thompson; J J McCarthy
Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys.
Journal of viral hepatitis 2011;18(8):571-9.
2011: Michael THOMAS Melia; Andrew J Muir; Kevin D Mullen; Stephanie Noviello; Frederick A Nunes; Natarajan Ravendhran; Mitchell L Shiffman; Mark S Sulkowski; Janice K Albrecht; Joseph R Bloomer; Navdeep Boparai; Clifford A Brass; Kimberly A Brown; Greg W Galler; Reem H Ghalib; Steven K Herrine; Ruiyun Jiang; John W King; Jonathan McCone; John G McHutchison
Racial differences in hepatitis C treatment eligibility.
Hepatology (Baltimore, Md.) 2011;54(1):70-8.
2011: Keyur Patel; Chen-Yuan Peng; Chutima Pramoolsinsap; Erik Pulkstenis; Samir R Shah; Ganesananthan Shanmuganathan; G. SUBRAMANIAN; Tawesak Tanwandee; Alexander J Thompson; Satawat Thongsawat; Mong Cho; Wan-Long Chuang; Paul J Clark; Graham R Foster; Kwang Hyup Han; Chuan-Mo Lee; Varocha Mahachai; John G McHutchison
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.
Journal of gastroenterology and hepatology 2011;26(7):1182-8.
2011: Keyur Patel; Alexander J Thompson; J Will Thompson; Hans L Tillmann; Diane Uzarski; Robert M Califf; Laura G Dubois; Geoffrey S Ginsburg; Joseph E Lucas; Jeanette J McCarthy; John G McHutchison; Martin A Moseley
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.
Hepatology (Baltimore, Md.) 2011;53(6):1809-18.
2011: Yuki Hitomi; Elizabeth T Cirulli; Jacques Fellay; John G McHutchison; Alexander J Thompson; Curtis E Gumbs; Kevin V Shianna; Thomas J Urban; David B Goldstein
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Gastroenterology 2011;140(4):1314-21.
2011: Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Paul J Clark; Susanna Naggie; Hans L Tillmann; Keyur Patel; Andrew J Muir; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Mario Romano; Fernando Sogari; Domenico Facciorusso; David B Goldstein; John G McHutchison; alessandra mangia
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Hepatology (Baltimore, Md.) 2011;53(2):389-95.
2011: Derek D Cyr; Joseph E Lucas; Paul J Clark; John G McHutchison; M Arthur Moseley; Keyur Patel; Alexander Thompson; J Will Thompson; Hans L Tillmann; Jeanette J McCarthy
Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C.
PloS one 2011;6(7):e21854.
2011: Nezam H Afdhal; John G McHutchison; Stefan Zeuzem; alessandra mangia; Jean-Michel Pawlotsky; Jeffrey S Murray; Kevin V Shianna; Yasuhito Tanaka; David L Thomas; David R Booth; David B Goldstein
Hepatitis C pharmacogenetics: state of the art in 2010.
Hepatology (Baltimore, Md.) 2011;53(1):336-45.
2011: Paul J Clark; Alex J Thompson; John G McHutchison
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
The American journal of gastroenterology 2011;106(1):38-45.
2010: Thomas J Urban; Alexander J Thompson; Shelton S Bradrick; Jacques Fellay; Detlef Schuppan; Kenneth D Cronin; Linda Hong; Alexander McKenzie; Keyur Patel; Kevin V Shianna; John G McHutchison; David B Goldstein; Nezam H Afdhal
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2010;52(6):1888-96.
2010: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Keyur Patel; Hans L Tillmann; Paul J Clark; Susanna Naggie; Jacques Fellay; Dongliang Ge; Jeanette J McCarthy; David B Goldstein; John G McHutchison
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
Hepatology (Baltimore, Md.) 2010;52(6):2243-4.
2010: Mark S Sulkowski; Mitchell L Shiffman; Nezam H Afdhal; K Rajender Reddy; Jonathan McCone; William M Lee; Steven K Herrine; Stephen A Harrison; F Fred Poordad; Kenneth Koury; Weiping Deng; Stephanie Noviello; Lisa Pedicone; Clifford A Brass; Janice K Albrecht; John G McHutchison
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
Gastroenterology 2010;139(5):1602-11, 1611.e1.
2010: Hans L Tillmann; Alex J Thompson; Keyur Patel; Manfred Wiese; Hannelore Tenckhoff; Hans D Nischalke; Yuliya Lokhnygina; Ulrike Kullig; Uwe Göbel; Emanuela Capka; Johannes Wiegand; Ingolf Schiefke; Wolfgang Güthoff; Kurt Grüngreiff; Ingrid König; Ulrich Spengler; Jeanette McCarthy; Kevin V Shianna; David B Goldstein; John G McHutchison; Jörg Timm; Jacob Nattermann
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.
Gastroenterology 2010;139(5):1586-92, 1592.e1.
2010: David R Nelson; Yves Benhamou; Wan-Long Chuang; Eric J Lawitz; Maribel Rodriguez-Torres; Robert Flisiak; Jens W F Rasenack; Wieslaw Kryczka; Chuan-Mo Lee; Vincent G Bain; Stephen Pianko; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; G. SUBRAMANIAN; John G McHutchison
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology 2010;139(4):1267-76.
2010: Stefan Zeuzem; Mark S Sulkowski; Eric J Lawitz; Vinod K Rustgi; Maribel Rodriguez-Torres; Bruce R Bacon; Mircea Grigorescu; Alan D Tice; Yoav Lurie; Janusz Cianciara; Andrew J Muir; Patrick W Cronin; Erik Pulkstenis; G. SUBRAMANIAN; John G McHutchison
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Gastroenterology 2010;139(4):1257-66.
2010: Alexander J Thompson; Jacques Fellay; Keyur Patel; Hans L Tillmann; Susanna Naggie; Dongliang Ge; Thomas J Urban; Kevin V Shianna; Andrew J Muir; Michael W Fried; Nezam H Afdhal; David B Goldstein; John G McHutchison
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Gastroenterology 2010;139(4):1181-9.
2010: Alex J Thompson; Paul J Clark; John G McHutchison
Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies.
Hepatology (Baltimore, Md.) 2010;52(3):1162-4.
2010: alessandra mangia; Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Hans L Tillmann; Keyur Patel; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Donato Bacca; Vito Carretta; Nicola Minerva; David B Goldstein; John G McHutchison
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Gastroenterology 2010;139(3):821-7, 827.e1.
2010: Jacqueline A Richmond; Donald E Bailey; Keyur Patel; Janet A Jezsik; Andrew Muir; Jr-Rung Lin; Shein-Chung Chow; Diane Uzarski; John G McHutchison
The use of complementary and alternative medicine by patients with chronic hepatitis C.
Complementary therapies in clinical practice 2010;16(3):124-31.
2010: Hans L Tillmann; John G McHutchison
Use of thrombopoietic agents for the thrombocytopenia of liver disease.
Seminars in hematology 2010;47(3):266-73.
2010: Jeanette J McCarthy; Josephine H Li; Alexander Thompson; Sunil Suchindran; Xiang Qian Lao; Keyur Patel; Hans L Tillmann; Andrew J Muir; John G McHutchison
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
Gastroenterology 2010;138(7):2307-14.
2010: Jacqueline A Richmond; Donald E Bailey; John G McHutchison; Andrew J Muir
The use of mind-body medicine and prayer among adult patients with chronic hepatitis C.
Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates 2010;33(3):210-6.
2010: Vijay K Agarwal; John G McHutchison; Jay H Hoofnagle
Important elements for the diagnosis of drug-induced liver injury.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010;8(5):463-70.
2010: John G McHutchison; Michael P Manns; Andrew J Muir; Norah A Terrault; Ira M Jacobson; Nezam H Afdhal; E Jenny Heathcote; Stefan Zeuzem; Hendrik W Reesink; Jyotsna Garg; Mohammad Bsharat; Shelley George; Robert S Kauffman; Nathalie Adda; Adrian M Di Bisceglie
Telaprevir for previously treated chronic HCV infection.
The New England journal of medicine 2010;362(14):1292-303.
2010: Jacques Fellay; Alexander J Thompson; Dongliang Ge; Curtis Gumbs; Thomas J Urban; Kevin V Shianna; Latasha D Little; Ping Qiu; Arthur H Bertelsen; Mark Watson; Amelia Warner; Andrew J Muir; Clifford Brass; Janice Albrecht; Mark S Sulkowski; John G McHutchison; David B Goldstein
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Nature 2010;464(7287):405-8.
2009: Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark S Sulkowski; John G McHutchison; David B Goldstein
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature 2009;461(7262):399-401.
2009: John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
The New England journal of medicine 2009;361(6):580-93.
2009: Avidan U Neumann; Stephen Pianko; Stefan Zeuzem; Eric M Yoshida; Yves Benhamou; Moshe Mishan; John G McHutchison; Erik Pulkstenis; G Mani Subramanian
Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.
Journal of hepatology 2009;51(1):21-8.
2009: John G McHutchison; Gregory T Everson; Stuart Gordon; Ira M Jacobson; Mark S Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
The New England journal of medicine 2009;360(18):1827-38.
2009: Keyur Patel; Y Benhamou; E M Yoshida; K D Kaita; S Zeuzem; Michael Torbenson; E Pulkstenis; G. SUBRAMANIAN; John G McHutchison
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Journal of viral hepatitis 2009;16(3):178-86.
2009: Seth Glickman; John G McHutchison; eric peterson; Charles Cairns; Robert A Harrington; Robert M Califf; Kevin Schulman
Ethical and scientific implications of the globalization of clinical research.
The New England journal of medicine 2009;360(8):816-23.
2009: Hans L Tillmann; Keyur Patel; John G McHutchison
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Current gastroenterology reports 2009;11(1):5-14.
2009: David R Nelson; Vinod Rustgi; Vijayan Balan; Mark S Sulkowski; Gary L Davis; Andrew J Muir; Louis R Lambiase; Rolland C Dickson; Russell H Weisner; Michele Fiscella; Patrick W Cronin; Erik Pulkstenis; John G McHutchison; G. SUBRAMANIAN
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2009;7(2):212-8.
2009: Alex Thompson; Keyur Patel; Hans Tillman; John G McHutchison
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
Journal of hepatology 2009;50(1):184-94.
2008: James Rochon; Petr Protiva; Leonard B Seeff; Robert J Fontana; Suthat Liangpunsakul; Paul B Watkins; Timothy Davern; John G McHutchison
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
Hepatology (Baltimore, Md.) 2008;48(4):1175-83.
2008: Stefan Zeuzem; Eric M Yoshida; Yves Benhamou; Stephen Pianko; Vincent G Bain; Daniel Shouval; Robert Flisiak; Vratislav Rehak; Mircea Grigorescu; Kelly Kaita; Patrick W Cronin; Erik Pulkstenis; G. SUBRAMANIAN; John G McHutchison
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Hepatology (Baltimore, Md.) 2008;48(2):407-17.
2008: Eric Lawitz; Maribel Rodriguez-Torres; Andrew J Muir; Tara L Kieffer; Lindsay McNair; Ariya Khunvichai; John G McHutchison
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
Journal of hepatology 2008;49(2):163-9.
2008: Karen R Canlas; Brian M Dobozi; Sauyu Lin; Alastair D Smith; Don C Rockey; Andrew J Muir; Naurang M Agrawal; Martin H Poleski; Keyur Patel; John G McHutchison
Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia.
Journal of clinical gastroenterology 2008;42(7):844-8.
2008: Hans L Tillmann; Keyur Patel; John G McHutchison
GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality.
Gastroenterology 2008;134(7):2191; author reply 2191-2.
2008: Vincent G Bain; Kelly D Kaita; Paul Marotta; Eric M Yoshida; Mark G Swain; Robert J Bailey; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; John G McHutchison; G. SUBRAMANIAN
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(6):701-6.
2008: Hans L Tillmann; John G McHutchison
Telbivudine versus lamivudine in patients with chronic hepatitis B.
The New England journal of medicine 2008;358(14):1517; author reply 1517-8.
2008: John G McHutchison; Keyur Patel; Eugene R Schiff; N Gitlin; R E Mur; G T Everson; R L Carithers; G L Davis; P Marcellin; Mitchell L Shiffman; J Harvey; Janice K Albrecht
Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
Alimentary pharmacology & therapeutics 2008;27(5):422-32.
2008: Keyur Patel; David R Nelson; Don C Rockey; Nezam H Afdhal; Katie M Smith; Esther Oh; Keith Hettinger; Marc Vallée; Anouk Dev; Margaret Smith-Riggs; John G McHutchison
Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(2):242-7.
2008: Anouk T Dev; Teresa L Kauf; Amany Zekry; Keyur Patel; Karen Heller; Kevin Schulman; John G McHutchison
Factors influencing the participation of gastroenterologists and hepatologists in clinical research.
BMC health services research 2008;8():208.
2007: John G McHutchison; Bruce R Bacon; Glenda S Owens
Making it happen: managed care considerations in vanquishing hepatitis C.
The American journal of managed care 2007;13 Suppl 12():S327-36; quiz S337-40.
2007: Bruce R Bacon; John G McHutchison
Into the light: strategies for battling hepatitis C.
The American journal of managed care 2007;13 Suppl 12():S319-26.
2007: G. SUBRAMANIAN; Michele Fiscella; Araba Lamousé-Smith; Stefan Zeuzem; John G McHutchison
Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.
Nature biotechnology 2007;25(12):1411-9.
2007: John G McHutchison; Geoffrey Dusheiko; Mitchell L Shiffman; Maribel Rodriguez-Torres; Samuel Sigal; Marc Bourliere; Thomas Berg; Stuart Gordon; Fiona M Campbell; Dickens Theodore; Nicole Blackman; Julian Jenkins; Nezam H Afdhal
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
The New England journal of medicine 2007;357(22):2227-36.
2007: John G McHutchison; Bruce R Bacon; Stuart Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H Afdhal; Ira M Jacobson; Andrew Muir; Mohammed J Al Adhami; Mary Lou Morris; Julie Lekstrom-Himes; Susan M Efler; Heather L Davis
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
Hepatology (Baltimore, Md.) 2007;46(5):1341-9.
2007: Paul J Pockros; Eugene R Schiff; Mitchell L Shiffman; John G McHutchison; Robert G Gish; Nezam H Afdhal; Manana Makhviladze; Mira Huyghe; David Hecht; Tilman Oltersdorf; David A Shapiro
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2007;46(2):324-9.
2007: Paul J Pockros; Dominque Guyader; Heather M Patton; Myron J Tong; Terry Wright; John G McHutchison; Tze-Chiang Meng
Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
Journal of hepatology 2007;47(2):174-82.
2007: Jean-Michel Pawlotsky; Stéphane Chevaliez; John G McHutchison
The hepatitis C virus life cycle as a target for new antiviral therapies.
Gastroenterology 2007;132(5):1979-98.
2007: John G McHutchison; Michael P Manns; Robert S Brown; K Rajender Reddy; Mitchell L Shiffman; John Wong
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
The American journal of gastroenterology 2007;102(4):880-9.
2007: Ian R White; Keyur Patel; William T Symonds; Anouk Dev; Philip Griffin; Nikos Tsokanas; Mark Skehel; Chiang Liu; Amany Zekry; Paul Cutler; Mahanandeeshwar Gattu; Don C Rockey; Michelle M Berrey; John G McHutchison
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection.
Journal of translational medicine 2007;5():33.
2006: Andrew J Muir; John G McHutchison
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Hepatology (Baltimore, Md.) 2006;44(6):1400-3.
2006: Vincent G Bain; Eric M Yoshida; Kelly D Kaita; Mark G Swain; E Jenny Heathcote; Andy Garcia; Paul Moore; Ren Yu; John G McHutchison; G. SUBRAMANIAN
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa.
Hepatology research : the official journal of the Japan Society of Hepatology 2006;35(4):256-62.
2006: Anouk Dev; Keyur Patel; Andrew Conrad; Lawrence M Blatt; John G McHutchison
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(6):797-801.
2006: John G McHutchison; Michael P Manns; Dan Longo
Definition and management of anemia in patients infected with hepatitis C virus.
Liver international : official journal of the International Association for the Study of the Liver 2006;26(4):389-98.
2006: Rebecca Lim; Belinda Knight; Keyur Patel; John G McHutchison; George C T Yeoh; John K Olynyk
Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo.
Hepatology (Baltimore, Md.) 2006;43(5):1074-83.
2006: Keyur Patel; Andrew J Muir; John G McHutchison
Diagnosis and treatment of chronic hepatitis C infection.
BMJ (Clinical research ed.) 2006;332(7548):1013-7.
2006: Vincent G Bain; Kelly D Kaita; Eric M Yoshida; Mark G Swain; E Jenny Heathcote; Avidan U Neumann; Michele Fiscella; Ren Yu; Blaire L Osborn; Patrick W Cronin; William W Freimuth; John G McHutchison; G. SUBRAMANIAN
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Journal of hepatology 2006;44(4):671-8.
2006: Keyur Patel; Suzanne Norris; Lauralynn Lebeck; Anne Feng; Michael Clare; Stephen Pianko; Bernard Portmann; Lawrence M Blatt; James A Koziol; Andrew Conrad; John G McHutchison
HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2006;43(2):241-9.
2006: John G McHutchison; Ralf Bartenschlager; Keyur Patel; Jean-Michel Pawlotsky
The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
Journal of hepatology 2006;44(2):411-21.
2006: Jules L Dienstag; John G McHutchison
American Gastroenterological Association technical review on the management of hepatitis C.
Gastroenterology 2006;130(1):231-64; quiz 214-7.
2006: John G McHutchison; Keyur Patel; Paul J Pockros; Lisa Nyberg; Stephen Pianko; Zhengrong Yu; F Andrew Dorr; T Jesse Kwoh
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
Journal of hepatology 2006;44(1):88-96.
2005: William C Grant; Ravi Jhaveri; John G McHutchison; Kevin Schulman; Teresa L Kauf
Trends in health care resource use for hepatitis C virus infection in the United States.
Hepatology (Baltimore, Md.) 2005;42(6):1406-13.
2005: Bruce R Bacon; John G McHutchison
Treatment issues with chronic hepatitis C: special populations and pharmacy strategies.
The American journal of managed care 2005;11(10 Suppl):S296-306; quiz S307-11.
2005: John G McHutchison; Bruce R Bacon
Chronic hepatitis C: an age wave of disease burden.
The American journal of managed care 2005;11(10 Suppl):S286-95; quiz S307-11.
2005: Keyur Patel; Amany Zekry; John G McHutchison
Steatosis and chronic hepatitis C virus infection: mechanisms and significance.
Clinics in liver disease 2005;9(3):399-410, vi.
2005: Steven L Condron; Michael A Heneghan; Keyur Patel; Anouk Dev; John G McHutchison; Andrew J Muir
Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection.
Transplantation 2005;80(1):145-8.
2005: Amany Zekry; John G McHutchison; Anna Mae Diehl
Insulin resistance and steatosis in hepatitis C virus infection.
Gut 2005;54(7):903-6.
2005: Amany Zekry; Keyur Patel; John G McHutchison
Treatment of acute hepatitis C infection: more pieces of the puzzle?
Journal of hepatology 2005;42(3):293-6.
2005: Stephen J Rulyak; Sue C Eng; Keyur Patel; John G McHutchison; Stuart Gordon; Kris V Kowdley
Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.
The American journal of gastroenterology 2005;100(2):332-7.
2005: John G McHutchison; Mitchell L Shiffman; Ramsey C Cheung; Stuart Gordon; Teresa L Wright; John C Pottage; Lindsay McNair; Ene I Ette; Scott Moseley; John Alam
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Antiviral therapy 2005;10(5):635-43.
2005: Keyur Patel; Jeff Albrecht; Erin Owens; Anouk Dev; Shanon Heaton; Stephen Pianko; Paul J Pockros; Andrew Conrad; Lawrence M Blatt; John G McHutchison
The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.
Antiviral therapy 2005;10(4):535-41.
2004: Muriel Soler; John G McHutchison; T Jesse Kwoh; F Andrew Dorr; Jean-Michel Pawlotsky
Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
Antiviral therapy 2004;9(6):953-68.
2004: Keyur Patel; Stuart Gordon; Ira Jacobson; Christophe Hézode; Esther Oh; Katie M Smith; Jean-Michel Pawlotsky; John G McHutchison
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.
Journal of hepatology 2004;41(6):935-42.
2004: Amany Zekry; Keyur Patel; Andrew Muir; John G McHutchison
Tinkering and tailoring with HCV therapy: can we get away with less?
Hepatology (Baltimore, Md.) 2004;40(6):1249-51.
2004: Anouk Dev; Keyur Patel; John G McHutchison
Hepatitis C and steatosis.
Clinics in liver disease 2004;8(4):881-92, ix.
2004: Keyur Patel; John G McHutchison
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.
Cleveland Clinic journal of medicine 2004;71 Suppl 3():S8-12.
2004: Deborah Shatin; Stephanie D Schech; Keyur Patel; John G McHutchison
Population-based hepatitis C surveillance and treatment in a national managed care organization.
The American journal of managed care 2004;10(4):250-6.
2004: Heather M Patton; Keyur Patel; cynthia behling; David Bylund; Lawrence M Blatt; Marc Vallée; Shanon Heaton; Andrew Conrad; Paul J Pockros; John G McHutchison
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
Journal of hepatology 2004;40(3):484-90.
2004: John G McHutchison
Understanding hepatitis C.
The American journal of managed care 2004;10(2 Suppl):S21-9.
2004: John G McHutchison; Bruce R Bacon
Hepatitis C: a 20-year debt comes due.
The American journal of managed care 2004;10(2 Suppl):S20.
2004: John G McHutchison; Anouk Dev
Future trends in managing hepatitis C.
Gastroenterology clinics of North America 2004;33(1 Suppl):S51-61.
2004: Alexander Monto; Keyur Patel; Alan Bostrom; Stephen Pianko; Paul J Pockros; John G McHutchison; Teresa L Wright
Risks of a range of alcohol intake on hepatitis C-related fibrosis.
Hepatology (Baltimore, Md.) 2004;39(3):826-34.
2004: Jean-Michel Pawlotsky; John G McHutchison
Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.
Hepatology (Baltimore, Md.) 2004;39(2):554-67.
2004: Anouk Dev; Keyur Patel; John G McHutchison
New therapies for chronic hepatitis C virus infection.
Current gastroenterology reports 2004;6(1):77-86.
2003: John Wong; Gary L Davis; John G McHutchison; Michael P Manns; Janice K Albrecht
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
The American journal of gastroenterology 2003;98(11):2354-62.
2003: Anouk Dev; Keyur Patel; Andrew Muir; John G McHutchison
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
The American journal of gastroenterology 2003;98(11):2344-7.
2003: Gary L Davis; John Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2003;38(3):645-52.
2003: Keyur Patel; John G McHutchison
Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.
Postgraduate medicine 2003;114(1):48-52, 57-9, 62.
2003: Keyur Patel; Anouk Dev; Andrew J Muir; John G McHutchison
Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
Hepatology (Baltimore, Md.) 2003;38(1):21-4.
2003: Paul J Pockros; Keyvr Patel; Christopher B O'Brien; Myron Tong; Coleman Smith; Vinod Rustgi; Robert L Carithers; John G McHutchison; Elizabeth Olek; Michael F Debruin
A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy.
Hepatology (Baltimore, Md.) 2003;37(6):1368-74.
2003: K Patel; A Muir; John G McHutchison; Heather M Patton
A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats.
The American journal of gastroenterology 2003;98(5):952-5.
2003: Keyur Patel; Andrew J Muir; John G McHutchison
Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients.
Hepatology (Baltimore, Md.) 2003;37(5):1222; author reply 1222-3.
2003: Keyur Patel; Adrianne Lajoie; Shanon Heaton; Stephen Pianko; cynthia behling; David Bylund; Paul J Pockros; Lawrence M Blatt; Andrew Conrad; John G McHutchison
Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.
Journal of gastroenterology and hepatology 2003;18(3):253-7.
2003: John G McHutchison; Michael W Fried
Current therapy for hepatitis C: pegylated interferon and ribavirin.
Clinics in liver disease 2003;7(1):149-61.
2003: R P Myers; K Patel; Stephen Pianko; T Poynard; John G McHutchison
The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.
Journal of viral hepatitis 2003;10(1):16-22.
2002: John G McHutchison; Keyur Patel
Future therapy of hepatitis C.
Hepatology (Baltimore, Md.) 2002;36(5 Suppl 1):S245-52.
2002: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules L Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
Gastroenterology 2002;123(4):1061-9.
2002: W F Reynolds; K Patel; Stephen Pianko; L M Blatt; J J Nicholas; John G McHutchison
A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection.
Genes and immunity 2002;3(6):345-9.
2002: Andrea Duchini; David C Redfield; John G McHutchison; Mathew E Brunson; Paul J Pockros
Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach.
Southern medical journal 2002;95(8):897-9.
2002: Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
Hepatology (Baltimore, Md.) 2002;36(1):211-8.
2002: Stephen Pianko; John G McHutchison; Stuart Gordon; Shanon Heaton; Zachary D Goodman; Keyur Patel; Cherise M Cortese; Elizabeth M Brunt; Bruce R Bacon; Lawrence M Blatt
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(4):483-9.
2002: John G McHutchison
Hepatitis C advances in antiviral therapy: what is accepted treatment now?
Journal of gastroenterology and hepatology 2002;17(4):431-41.
2002: Hugo Rosen; John G McHutchison; Andrew J Conrad; Jennifer J Lentz; Gail I Marousek; Steven L Rose; Atif Zaman; Kent Taylor; Sunwen Chou
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
The American journal of gastroenterology 2002;97(3):714-20.
2002: John G McHutchison; Thierry Poynard; Rafael Esteban-Mur; Gary L Davis; Zachary D Goodman; Joann Harvey; Mei-Hsiu Ling; Jean-Jacques Garaud; Janice K Albrecht; Keyur Patel; Jules L Dienstag; Timothy Morgan
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
Hepatology (Baltimore, Md.) 2002;35(3):688-93.
2001: John G McHutchison; J A Shad; Stuart Gordon; Timothy R Morgan; Mei-Hsiu Ling; Jean-Jacques Garaud; Janice K Albrecht; Jules L Dienstag
Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
Journal of viral hepatitis 2001;8(6):414-20.
2001: Michael P Manns; John G McHutchison; Stuart Gordon; Vinod Rustgi; Mitchell Shiffman; Robert W Reindollar; Zachary D Goodman; K Koury; M Ling; Janice K Albrecht
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet 2001;358(9286):958-65.
2001: J A Shad; John G McHutchison
Current and future therapies of hepatitis C.
Clinics in liver disease 2001;5(2):335-59.
2001: John G McHutchison; R Ponnudurai; David Bylund; A Anguiano; Paul J Pockros; T Mondala; L B Wilkes
Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial.
Journal of clinical gastroenterology 2001;32(2):133-7.
2001: John G McHutchison; John Ware; martha bayliss; Stephen Pianko; Janice K Albrecht; S Cort; I Yang; M P Neary
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
Journal of hepatology 2001;34(1):140-7.
2000: Andrea Duchini; John G McHutchison; Paul J Pockros
LKM-positive autoimmune hepatitis in the western United States: a case series.
The American journal of gastroenterology 2000;95(11):3238-41.
2000: John G McHutchison; T Poynard; Stephen Pianko; Stuart Gordon; A E Reid; Jules L Dienstag; T Morgan; R Yao; Jeff Albrecht
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.
Gastroenterology 2000;119(5):1317-23.
2000: John G McHutchison; Lawrence M Blatt; M de Medina; J R Craig; Andrew Conrad; Eugene R Schiff; Myron J Tong
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group.
Journal of gastroenterology and hepatology 2000;15(8):945-51.
2000: Stuart Gordon; JW Fang; Ann L. Silverman; John G McHutchison; Janice K Albrecht
The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.
Hepatology (Baltimore, Md.) 2000;32(2):400-4.
2000: Stephen Pianko; John G McHutchison
Treatment of hepatitis C with interferon and ribavirin.
Journal of gastroenterology and hepatology 2000;15(6):581-6.
2000: Lawrence M Blatt; Milton G Mutchnick; Myron J Tong; Franklin M Klion; Edward Lebovics; B Freilich; N Bach; C Smith; J Herrera; Hillel Tobias; Andrew Conrad; P Schmid; John G McHutchison
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States.
Journal of viral hepatitis 2000;7(3):196-202.
1999: John G McHutchison; G Giannelli; Lisa Nyberg; Lawrence M Blatt; K Waite; P Mischkot; Stephen Pianko; Andrew Conrad; P Grint
A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(11):1265-70.
1999: Zobair M Younossi; Mendel E Singer; John G McHutchison; Kenneth M Shermock
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Hepatology (Baltimore, Md.) 1999;30(5):1318-24.
1999: John G McHutchison; Lawrence M Blatt; R Ponnudurai; K Goodarzi; J Russell; Andrew Conrad
Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection.
Journal of medical virology 1999;57(4):351-5.
1999: John G McHutchison; T Poynard
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
Seminars in liver disease 1999;19 Suppl 1():57-65.
1998: John G McHutchison; Stuart Gordon; Eugene R Schiff; ML Shiffman; W M Lee; Vinod Rustgi; Zachary D Goodman; Mei-Hsiu Ling; S Cort; Janice K Albrecht
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
The New England journal of medicine 1998;339(21):1485-92.
1998: Zobair M Younossi; John G McHutchison; CN Broussard; David Cloutier; A Sedghi-Vaziri
Portal decompression by transjugular intrahepatic portosystemic shunt and changes in serum-ascites albumin gradient.
Journal of clinical gastroenterology 1998;27(2):149-51.
1998: Lawrence M Blatt; Myron J Tong; John G McHutchison; J Russell; P Schmid; Andrew Conrad
Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(2):75-80.
1997: Myron J Tong; Lawrence M Blatt; John G McHutchison; RL Co; Andrew Conrad
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
Hepatology (Baltimore, Md.) 1997;26(6):1640-5.
1997: John G McHutchison; Omana V Nainan; Miriam J Alter; A Sedghi-Vaziri; Jill Detmer; M Collins; Janice A Kolberg
Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA.
Hepatology (Baltimore, Md.) 1997;26(5):1322-7.
1997: Z M Younossi; John G McHutchison; T G Ganiats
An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis.
Journal of hepatology 1997;27(2):295-8.
1997: John G McHutchison
Differential diagnosis of ascites.
Seminars in liver disease 1997;17(3):191-202.